Phase II clinical trial of the first-line Stop-and-Go modified FOLFOX6 and bevacizmab for patients with unresectable/recurrent colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2616726
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: After 8 cycles of modified FOLFOX 6 with bevacizmab, patients receive sLV5FU2 with bevacizumab (until 8 cycles are completed or disease progression). And then, patients receive modified FOLFOX6 with bevacizmab (until 8 cycles are completed or disease progression.)
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
创建时间：
2007-08-15
